STAB logo

Statera Biopharma (STAB) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

28 July 2021

Indexes:

Not included

Description:

Statera Biopharma focuses on developing innovative therapies for autoimmune and inflammatory diseases. The company aims to improve patient outcomes by creating treatments that restore balance in the immune system. Their research combines advanced science with a commitment to addressing unmet medical needs.

Events Calendar

Earnings

Next earnings date:

Nov 29, 2024

Recent quarterly earnings:

Nov 15, 2021

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Jan 28, 2015

Analyst ratings

Recent major analysts updates

No data about analysts updates

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

BNP Paribas Primary New Issues: STAB Notice B&M
BNP Paribas Primary New Issues: STAB Notice B&M
BNP Paribas Primary New Issues: STAB Notice B&M
STAB
globenewswire.com22 November 2024

22 November, 2024 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. B&M (BME LN) Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT [Further to the pre-stabilisation period announcement dated 19 th November 2024  BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

BNP Paribas Primary New Issues: NO STAB Notice: TUI CRUISES
BNP Paribas Primary New Issues: NO STAB Notice: TUI CRUISES
BNP Paribas Primary New Issues: NO STAB Notice: TUI CRUISES
STAB
globenewswire.com22 November 2024

[22/11/2024] Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. TUI CRUISES GMBH Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT [Further to the pre-stabilisation period announcement dated 19/11/2024 BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

Correction: BNP Paribas Primary New Issues: Post-Stab - No STAB Notice - Webuild Spa
Correction: BNP Paribas Primary New Issues: Post-Stab - No STAB Notice - Webuild Spa
Correction: BNP Paribas Primary New Issues: Post-Stab - No STAB Notice - Webuild Spa
STAB
globenewswire.com23 October 2024

23/10/2024 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. Webuild SpA Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT [Further to the pre-stabilisation period announcement dated 22/10/2024 BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

BNP Paribas Primary New Issues: STAB Notice
BNP Paribas Primary New Issues: STAB Notice
BNP Paribas Primary New Issues: STAB Notice
STAB
globenewswire.com23 October 2024

23/10/2024 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. Webuild SpA Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT [Further to the pre-stabilisation period announcement dated 22/10/2024 BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

BNP Paribas Primary New Issues: Post Stab - No STAB Notice - LION/POLARIS (PICARD)
BNP Paribas Primary New Issues: Post Stab - No STAB Notice - LION/POLARIS (PICARD)
BNP Paribas Primary New Issues: Post Stab - No STAB Notice - LION/POLARIS (PICARD)
STAB
globenewswire.com23 October 2024

23/10/2024 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. LION/POLARIS LUX 4 S.A Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT [Further to the pre-stabilisation period announcement dated 22/10/2024 BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

BNP Paribas Primary New Issues: Post Stab - No STAB Notice - ACCORINVEST GROUP S.A
BNP Paribas Primary New Issues: Post Stab - No STAB Notice - ACCORINVEST GROUP S.A
BNP Paribas Primary New Issues: Post Stab - No STAB Notice - ACCORINVEST GROUP S.A
STAB
globenewswire.com23 October 2024

23/10/2024 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. ACCORINVEST GROUP S.A Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT [Further to the pre-stabilisation period announcement dated 22/10/2024 BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

BNP Paribas Primary New Issues: Post Stab - No STAB - ILIAD S.A
BNP Paribas Primary New Issues: Post Stab - No STAB - ILIAD S.A
BNP Paribas Primary New Issues: Post Stab - No STAB - ILIAD S.A
STAB
globenewswire.com23 October 2024

23/10/2024 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. ILIAD S.A Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT Further to the pre-stabilisation period announcement dated 22/10/2024 BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

BNP Paribas Primary New Issues: Sammontana No STAB Notice
BNP Paribas Primary New Issues: Sammontana No STAB Notice
BNP Paribas Primary New Issues: Sammontana No STAB Notice
STAB
globenewswire.com07 October 2024

7TH October 2024   Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. SAMMONTANA ITALIA S.p.A.

BNP Paribas Primary New Issues: STAB Notice
BNP Paribas Primary New Issues: STAB Notice
BNP Paribas Primary New Issues: STAB Notice
STAB
globenewswire.com02 October 2024

02/10/2024 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. CMA CGM Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT [Further to the pre-stabilisation period announcement dated [01/10/2024]] BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

BNP Paribas Primary New Issues: STAB Notice - NO STAB - AZELIS Finance NV
BNP Paribas Primary New Issues: STAB Notice - NO STAB - AZELIS Finance NV
BNP Paribas Primary New Issues: STAB Notice - NO STAB - AZELIS Finance NV
STAB
globenewswire.com17 September 2024

[17.09.2024] Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. [AZELIS FINANCE NV] Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT Further to the pre-stabilisation period announcement dated [11.09.2024] BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the primary business of Statera Biopharma?
  • What is the ticker symbol for Statera Biopharma?
  • Does Statera Biopharma pay dividends?
  • What sector is Statera Biopharma in?
  • What industry is Statera Biopharma in?
  • What country is Statera Biopharma based in?
  • When did Statera Biopharma go public?
  • Is Statera Biopharma in the S&P 500?
  • Is Statera Biopharma in the NASDAQ 100?
  • Is Statera Biopharma in the Dow Jones?
  • When was Statera Biopharma's last earnings report?
  • When does Statera Biopharma report earnings?

What is the primary business of Statera Biopharma?

Statera Biopharma focuses on developing innovative therapies for autoimmune and inflammatory diseases. The company aims to improve patient outcomes by creating treatments that restore balance in the immune system. Their research combines advanced science with a commitment to addressing unmet medical needs.

What is the ticker symbol for Statera Biopharma?

The ticker symbol for Statera Biopharma is NASDAQ:STAB

Does Statera Biopharma pay dividends?

No, Statera Biopharma does not pay dividends

What sector is Statera Biopharma in?

Statera Biopharma is in the Healthcare sector

What industry is Statera Biopharma in?

Statera Biopharma is in the Biotechnology industry

What country is Statera Biopharma based in?

Statera Biopharma is headquartered in United States

When did Statera Biopharma go public?

Statera Biopharma's initial public offering (IPO) was on 28 July 2021

Is Statera Biopharma in the S&P 500?

No, Statera Biopharma is not included in the S&P 500 index

Is Statera Biopharma in the NASDAQ 100?

No, Statera Biopharma is not included in the NASDAQ 100 index

Is Statera Biopharma in the Dow Jones?

No, Statera Biopharma is not included in the Dow Jones index

When was Statera Biopharma's last earnings report?

Statera Biopharma's most recent earnings report was on 15 November 2021

When does Statera Biopharma report earnings?

The next expected earnings date for Statera Biopharma is 29 November 2024